Search

Your search keyword '"Lawrance, I"' showing total 192 results
Start Over Author "Lawrance, I"
192 results on '"Lawrance, I"'

57. Cellular and molecular mediators of intestinal fibrosis in IBD

Author

Lawrance, I, Rogler, G, Bamias, G, Breynaert, Christine, Forholmen, J, Pellino, G, Reif, S, Speca, S, and Latella, G

Subjects
Science & Technology, FIBROBLAST GROWTH-FACTORS, Gastroenterology & Hepatology, interleukin, extracellular matrix, SMOOTH-MUSCLE-CELLS, chemokine, HUMAN COLONIC MYOFIBROBLASTS, INDUCED PULMONARY FIBROSIS, growth factor, TGF-BETA, HEPATIC STELLATE CELLS, EPITHELIAL-MESENCHYMAL TRANSITION, myofibroblast, fibroblast, CROHNS-DISEASE, inflammatory bowel disease, intestinal fibrosis, RENAL FIBROSIS, Life Sciences & Biomedicine, INFLAMMATORY-BOWEL-DISEASE
Abstract

Intestinal fibrosis is a major complication of the inflammatory bowel diseases (IBD) and although inflammation is necessary for its development, it would appear that it plays a minor role in its progression as anti-inflammatory treatments in IBD do not prevent fibrosis once it has started. The processes that regulate fibrosis would thus appear to be distinct from those regulating inflammation and, therefore, a detailed understanding of these pathways is vital to the development of anti-fibrogenic strategies. There have been several recent reviews exploring what is known, and what remains unknown, about the development of intestinal fibrosis. This review is designed to add to this literature but with a focus on the cellular components that are involved in the development of fibrogenesis and the major molecular mediators that impact on these cells. The aim is to heighten the understanding of the factors involved in intestinal fibrogenesis so that detailed research can be encouraged in order to advance the processes that could lead to effective treatments. ispartof: Journal of Crohns & Colitis vol:11 issue:12 pages:1491-1503 ispartof: location:England status: published

Published
2017

59. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

Author

Sandborn, Wj, Feagan, Bg, Rutgeerts, P, Hanauer, S, Colombel, Jf, Sands, Be, Lukas, M, Fedorak, Rn, Lee, S, Bressler, B, Fox, I, Rosario, M, Sankoh, S, Xu, J, Stephens, K, Milch, C, Parikh, A, Bampton P, GEMINI 2 Study G. r. o. u. p., Borody, T, Chung, A, Debinski, H, Florin, T, Hetzel, D, Jakobovits, S, Lawrance, I, Leong, R, Macrae, F, Mitchell, B, Moore, G, Pavli, P, Samuel, D, Weltman, M, Haas, T, Reinisch, W, Vogel, W, Baert, F, De Maeyer, M, De Vos, M, Dewit, O, D'Haens, G, Louis, E, Muls, V, Van Assche, G, Krastev, Z, Nikolovska, D, Petrov, P, Petrov, A, Stoinov, S, Tchernev, K, Vasileva, G, Aumais, G, Axler, J, Bailey, R, Bernstein, C, Bitton, A, Bourdages, R, Cohen, A, Devroede, G, Dhalla, S, Feagan, B, Fedorak, R, Green, D, Greenberg, G, Jones, J, Larkai, E, Macintosh, D, Panaccione, R, Ponich, T, Singh, R, Sy, R, Wiesinger, H, Albin, A, Douda, L, Horny, I, Stehlik, J, Stuksa, J, Volfova, M, Vyhnalek, P, Zadorova, Z, Andersen, V, Bendtsen, F, Fallingborg, J, Rannem, T, Maelt, A, Margus, B, Salupere, R, Allez, M, Des Varennes SB, Desreumaux, P, Dupas, Jl, Grimaud, Jc, Hebuterne, X, Lerebours, E, Picon, L, Zerbib, F, Aldinger, V, Baumgart, D, Buening, C, Dollinger, M, Hoffmann, P, Howaldt, S, Klaus, J, Konturek, Jw, Krummenerl, T, Malfertheiner, P, Schmidt, W, Schreiber, S, Seidler, U, Stallmach, A, Stremmel, W, Zeitz, M, Mantzaris, G, Triantafyllou, K, Ng, C, Bene, L, Fazekas, I, Fejes, R, Gall, J, Horvat, G, Hunyady, B, Salamon, A, Toth, T, Tulassay, Z, Varga, E, Varga, M, Varga Szabo, L, Vincze, A, Oddsson, E, Örvar, K, Ahuja, V, Amarapurkar, D, Chandra, A, Koshy, A, Krishna, P, Ramakrishna, K, Reddy, N, Thorat, V, Patchett, S, Ryan, B, Ben Horin, S, Fishman, S, Lavy, A, Rachmilewitz, D, Ardizzone, S, Corazziari, E, Danese, S, Fries, Walter, Gasbarrini, A, Kohn, A, Sturniolo, Gc, Danilans, A, George, Am, Hilmi, In, Engels, Lg, Ponsioen, Cy, van der Woude CJ, Gearry, R, Haines, M, Schultz, M, Wallace, I, Wyeth, J, Florholmen, J, Jahnsen, J, Lygren, I, Röseth, A, Ciecko Michalska, I, Gonciarz, M, Horynski, M, Huk, J, Jamrozik Kruk, Z, Janke, A, Klupinska, G, Marecik, J, Paradowski, L, Rudzinski, J, Rydzewska, G, Han, Ds, Hong, Sp, Kim, Hj, Kim, Js, Kim, Ko, Kim, Yh, Yang, Sk, Gheorghe, Ls, Voiosu, Rm, Alexeeva, O, Baranovsky, A, Bunkova, E, Burnevich, E, Dolgikh, O, Grinevich, V, Lakhin, A, Tarabar, D, Ling, Kl, Bunganic, I, Cernok, S, Gregus, M, Coetzer, T, Grundling, H, Moola, Sa, Wright, Jp, Ziady, C, Bermejo, F, Calvet, X, Herrerias, Jm, Perez Calle JL, Perez Gisbert, J, Hertervig, E, Karlen, P, Michetti, P, Rogler, G, Seibold, F, Wu, Dc, Atug, O, Kurdas, Oo, Datsenko, O, Dorofyeyev, A, Dudar, L, Golovchenko, O, Klyarits'Ka, I, Skrypnyk, I, Hawthorne, Ab, Middleton, S, Abreu, M, Bala, N, Becker, S, Behm, B, Braun, R, Bukhari, M, Chen, S, Coates, A, Dar, S, Dassopoulos, T, De Villiers, W, Desautels, S, Desta, T, Dimitroff, J, Dryden, G, Duvall, A, Farraye, F, Fein, S, Liu, Bf, Gatof, D, Geenen, D, Ginsburg, P, Glombicki, A, Glover, S, Gordon, G, Grisolano, S, Hanson, J, Hardi, R, Hoffman, B, Isaacs, K, Kim, C, Koval, G, Lashner, B, Lawitz, E, Leman, B, Levine, J, Loftus, E, Mahadevan, U, Mannon, P, Marcet, J, Matsuyama, R, Matusow, G, Mccabe, R, Mirkin, K, Murphy, M, Mushahwar, A, Mutlu, E, Nagrani, M, Nguyen, D, Nichols, M, Nieves Ramirez, A, Oubre, B, Pace, S, Pandak, W, Perera, L, Quadri, A, Quallich, L, Rajapakse, R, Randall, C, Regueiro, M, Safdi, A, Sandborn, W, Sands, B, Saubermann, L, Scherl, E, Schwartz, D, Sedghi, S, Shafran, I, Shepard, R, Siegel, C, Stein, L, Tatum, H, Triebling, A, Vasudeva, R, Winston, B, Wolf, D, Younes, Z, Jewell, D, Mahon, J, Rothstein, R, Snydman, D, Massaro, J, Clifford, D, Berger, J, Major, E, Provenzale, J, Lev, M., GEMINI 2 Study Group, Bampton, P., Borody, T., Chung, A., Debinski, H., Florin, T., Hetzel, D., Jakobovits, S., Lawrance, I., Leong, R., Macrae, F., Mitchell, B., Moore, G., Pavli, P., Samuel, D., Weltman, M., Haas, T., Reinisch, W., Vogel, W., Baert, F., De Maeyer, M., De Vos, M., Dewit, O., D'Haens, G., Louis, E., Muls, V., Van Assche, G., Krastev, Z., Nikolovska, D., Petrov, P., Petrov, A., Stoinov, S., Tchernev, K., Vasileva, G., Aumais, G., Axler, J., Bailey, R., Bernstein, C., Bitton, A., Bourdages, R., Bressler, B., Cohen, A., Devroede, G., Dhalla, S., Feagan, B., Fedorak, R., Green, D., Greenberg, G., Jones, J., Larkai, E., MacIntosh, D., Panaccione, R., Ponich, T., Singh, R., Sy, R., Wiesinger, H., Albin, A., Douda, L., Horny, I., Lukas, M., Stehlik, J., Stuksa, J., Volfova, M., Vyhnalek, P., Zadorova, Z., Andersen, V., Bendtsen, F., Fallingborg, J., Rannem, T., Maelt, A., Margus, B., Salupere, R., Allez, M., Des Varennes SB., Desreumaux, P., Dupas, JL., Grimaud, JC., Hebuterne, X., Lerebours, E., Picon, L., Zerbib, F., Aldinger, V., Baumgart, D., Buening, C., Dollinger, M., Hoffmann, P., Howaldt, S., Klaus, J., Konturek, JW., Krummenerl, T., Malfertheiner, P., Schmidt, W., Schreiber, S., Seidler, U., Stallmach, A., Stremmel, W., Zeitz, M., Mantzaris, G., Triantafyllou, K., Ng, C., Bene, L., Fazekas, I., Fejes, R., Gall, J., Horvat, G., Hunyady, B., Salamon, A., Toth, T., Tulassay, Z., Varga, E., Varga, M., Varga-Szabo, L., Vincze, A., Oddsson, E., Örvar, K., Ahuja, V., Amarapurkar, D., Chandra, A., Koshy, A., Krishna, P., Ramakrishna, K., Reddy, N., Thorat, V., Patchett, S., Ryan, B., Ben Horin, S., Fishman, S., Lavy, A., Rachmilewitz, D., Ardizzone, S., Corazziari, E., Danese, S., Fries, W., Gasbarrini, A., Kohn, A., Sturniolo, GC., Danilans, A., George, AM., Hilmi, IN., Engels, LG., Ponsioen, CY., van der Woude CJ., Gearry, R., Haines, M., Schultz, M., Wallace, I., Wyeth, J., Florholmen, J., Jahnsen, J., Lygren, I., Röseth, A., Ciecko-Michalska, I., Gonciarz, M., Horynski, M., Huk, J., Jamrozik-Kruk, Z., Janke, A., Klupinska, G., Marecik, J., Paradowski, L., Rudzinski, J., Rydzewska, G., Han, DS., Hong, SP., Kim, HJ., Kim, JS., Kim, KO., Kim, YH., Yang, SK., Gheorghe, LS., Voiosu, RM., Alexeeva, O., Baranovsky, A., Bunkova, E., Burnevich, E., Dolgikh, O., Grinevich, V., Lakhin, A., Tarabar, D., Ling, KL., Bunganic, I., Cernok, S., Gregus, M., Coetzer, T., Grundling, H., Moola, SA., Wright, JP., Ziady, C., Bermejo, F., Calvet, X., Herrerias, JM., Perez Calle JL., Perez Gisbert, J., Hertervig, E., Karlen, P., Michetti, P., Rogler, G., Seibold, F., Wu, DC., Atug, O., Kurdas, OO., Datsenko, O., Dorofyeyev, A., Dudar, L., Golovchenko, O., Klyarits'ka, I., Skrypnyk, I., Hawthorne, AB., Middleton, S., Abreu, M., Bala, N., Becker, S., Behm, B., Braun, R., Bukhari, M., Chen, S., Coates, A., Dar, S., Dassopoulos, T., De Villiers, W., Desautels, S., Desta, T., Dimitroff, J., Dryden, G., Duvall, A., Farraye, F., Fein, S., Liu, BF., Gatof, D., Geenen, D., Ginsburg, P., Glombicki, A., Glover, S., Gordon, G., Grisolano, S., Hanauer, S., Hanson, J., Hardi, R., Hoffman, B., Isaacs, K., Kim, C., Koval, G., Lashner, B., Lawitz, E., Lee, S., Leman, B., Levine, J., Loftus, E., Mahadevan, U., Mannon, P., Marcet, J., Matsuyama, R., Matusow, G., McCabe, R., Mirkin, K., Murphy, M., Mushahwar, A., Mutlu, E., Nagrani, M., Nguyen, D., Nichols, M., Nieves Ramirez, A., Oubre, B., Pace, S., Pandak, W., Perera, L., Quadri, A., Quallich, L., Rajapakse, R., Randall, C., Regueiro, M., Safdi, A., Sandborn, W., Sands, B., Saubermann, L., Scherl, E., Schwartz, D., Sedghi, S., Shafran, I., Shepard, R., Siegel, C., Stein, L., Tatum, H., Triebling, A., Vasudeva, R., Winston, B., Wolf, D., Younes, Z., Feagan, BG., Colombel, JF., Rutgeerts, P., Sandborn, WJ., Sands, BE., Jewell, D., Mahon, J., Rothstein, R., Snydman, D., Massaro, J., Clifford, D., Berger, J., Major, E., Provenzale, J., Lev, M., and Medical Microbiology & Infectious Diseases

Subjects
Adult, Male, Integrins, medicine.medical_specialty, HUMAN POLYOMAVIRUSES, JC, Antibodies/blood, Antibodies, Monoclonal, Humanized/adverse effects, Antibodies, Monoclonal, Humanized/immunology, Crohn Disease/drug therapy, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Glucocorticoids/therapeutic use, Humans, Immunosuppressive Agents/therapeutic use, Induction Chemotherapy, Infusions, Intravenous/adverse effects, Integrins/antagonists & inhibitors, Integrins/immunology, Maintenance Chemotherapy, Middle Aged, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, Antibodies, Monoclonal, Humanized, Placebo, Gastroenterology, Inflammatory bowel disease, Antibodies, Vedolizumab, CERTOLIZUMAB PEGOL, Natalizumab, Crohn Disease, Maintenance therapy, HUMANIZED ANTIBODY, Internal medicine, Ustekinumab, medicine, Certolizumab pegol, Infusions, Intravenous, Glucocorticoids, NATALIZUMAB, business.industry, Induction chemotherapy, General Medicine, medicine.disease, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, RELAPSING MULTIPLE-SCLEROSIS, INFLAMMATORY-BOWEL-DISEASE, HUMAN POLYOMAVIRUSES, HUMANIZED ANTIBODY, CERTOLIZUMAB PEGOL, ULCERATIVE-COLITIS, RANDOMIZED-TRIAL, NATALIZUMAB, JC, RANDOMIZED-TRIAL, digestive system diseases, Surgery, ULCERATIVE-COLITIS, RELAPSING MULTIPLE-SCLEROSIS, business, Immunosuppressive Agents, INFLAMMATORY-BOWEL-DISEASE, medicine.drug
Abstract

BACKGROUND: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6. In the maintenance trial, 461 patients who had had a response to vedolizumab were randomly assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52. RESULTS: At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab and 6.8% who received placebo were in clinical remission (i.e., had a score on the Crohn's Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to approximately 600 and higher scores indicating greater disease activity) (P=0.02); a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response (≥100-point decrease in the CDAI score) (P=0.23). Among patients in cohorts 1 and 2 who had a response to induction therapy, 39.0% and 36.4% of those assigned to vedolizumab every 8 weeks and every 4 weeks, respectively, were in clinical remission at week 52, as compared with 21.6% assigned to placebo (P

Published
2013

60. Risk of early-onset proliferative retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy

Author

Krolewski, Andrzej S., Barzilay, Joshua, Warram, James H., Martin, Blaise C., Pfeifer, Michael, and Rand, Lawrance I.

Subjects
Type 1 diabetes -- Complications and side effects -- Risk factors, Retinal diseases -- Risk factors -- Complications and side effects, Peripheral nerve diseases -- Risk factors -- Complications and side effects, Health, Complications and side effects, Risk factors
Abstract

Determinants of proliferative diabetic retinopathy (PDR) that occur during the 2nd decade of insulin-dependent diabetes mellitus (IDDM) (early-onset PDR) were investigated in a nested case-control study. From an inception cohort of patients with juvenile-onset IDDM that now has 15-21 yr diabetes duration, the patients with PDR (cases, n = 74) were selected for study along with a random sample of the patients in the cohort without a random (control subjects, n = 88). The risk of PDR was associated with poor glycemic control during the first 12 yr of diabetes. Relative to patients in the first quartile of the index of hyperglycemia, those in higher quartiles and nonattenders had a four- to fivefold risk of developing PDR. A striking relationship with cardiovascular autonomic neuropathy (CAN) was found. Relative to patients without CAN, patients with significant and mild CAN had odds ratios of 77.5 and 34.6, respectively. Patients with albumin excretion rates >30 μ /min had moderately increased risk of PDR (ranging from 4-fold for microalbuminuria to 7-fold for proteinuria). In contrast, patients with impaired renal function had an extremely high risk of PDR. All 20 of these patients were cases, therefore the odds ratio was infinite. All three factors (poor glycemic control, CAN, and various stages of nephropathy) were associated with PDR in multiple logistic regression analysis. However, in models including glycemic control, the association between microalbuminuria or proteinuria and PDR was weakened. In conclusion, our findings are consistent with a hypothesis that the level of glycemia is a primary determinant of early-onset PDR. Autonomic neuropathy, almost universal among cases, may be a strong risk factor for or a risk indicator or an etiologic process underlying the development of PDR. Conditions associated with advanced diabetic nephropathy, on the other hand, may accelerate the progression of nonproliferative retinopathy to PDR. Diabetes 41:430-37, 1992, Diabetic retinopathy may be divided into two stages; nonproliferative and proliferative. Non-proliferative retinopathy seems to be specific for diabetes and some degree of this complication develops in most juvenile-onset insulin-dependent [...]

Published
1992

61. P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)

Author

Pulusu, S S R, primary, Srinivasan, A, additional, Krishnaprasad, K, additional, Cheng, D, additional, Mogilevski, T, additional, Flanagan, E, additional, Keung, C, additional, Wu, C, additional, Prosser, R, additional, Sawyer, E, additional, Rizvi, Q -U -A, additional, Su, H, additional, Leung, W -K, additional, Edmundson, A, additional, Cooke, S, additional, Mahy, G, additional, Thin, L, additional, Radford-Smith, G, additional, Sparrow, M, additional, Andrews, J M, additional, Connor, S, additional, Bampton, P, additional, Ghaly, S, additional, Van Langenberg, D, additional, Bell, S, additional, De Cruz, P, additional, Begun, J, additional, Ng, S, additional, Travis, S, additional, and Lawrance, I, additional

Published
2018
Full Text
View/download PDF

64. Adalimumab and Infliximab clearance in neonates (Era Study)

Author

Julsgaard (Mette Julsgaard Nielsen), Mette, Christensen, L A, Gibson, P. R., Gearry, R., Fallingborg, Jan, Bibby, Bo Martin, Kjeldsen, J., Wildt, S., Svenningsen, L., Connell, W., Hvas, Christian Lodberg, Sparrow, M. P., Walsh, A., Connor, S. J., Radford-Smith, G., Lawrance, I, Andrews, J. M., Ellard, K., Uldbjerg, N., Rosella, O., Grosen, A., and Bell, S. J.

Published
2015

65. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Author

Regueiro, Miguel, primary, Feagan, Brian G., additional, Zou, Bin, additional, Johanns, Jewel, additional, Blank, Marion A., additional, Chevrier, Marc, additional, Plevy, Scott, additional, Popp, John, additional, Cornillie, Freddy J., additional, Lukas, Milan, additional, Danese, Silvio, additional, Gionchetti, Paolo, additional, Hanauer, Stephen B., additional, Reinisch, Walter, additional, Sandborn, William J., additional, Sorrentino, Dario, additional, Rutgeerts, Paul, additional, Debinski, H., additional, Florin, T., additional, Hetzel, D., additional, Lawrance, I., additional, Radford-Smith, G., additional, Sloss, A., additional, Sorrentino, D., additional, Gassner, S., additional, Haas, T., additional, Reicht, G., additional, Reinisch, W., additional, Strasser, M., additional, Vogelsang, H., additional, Bossuyt, P., additional, DeWit, O., additional, D'Haens, G., additional, Franchimont, D., additional, Louis, E., additional, Vermeire, S., additional, Bernstein, C.N., additional, Bourdages, R., additional, Chiba, N., additional, Dhalla, S.S., additional, Feagan, B.G., additional, Fedorak, R.N., additional, Lachance, J.R., additional, Panaccione, R., additional, Ropeleski, M., additional, Singh Salh, B., additional, Lukas, M, additional, Colombel, J-F, additional, Allez, M., additional, Desreumaux, P., additional, Dupas, J.L., additional, Grimaud, J-C., additional, Hebuterne, X., additional, Laharie, D., additional, Lerebours, E., additional, Peyrin-Biroulet, L., additional, Reimund, J-M., additional, Viennot, S., additional, Zerbib, F., additional, Antoni, C., additional, Atreya, R., additional, Baumgart, D.C., additional, Berg, C., additional, Boecker, U., additional, Bramkamp, G., additional, Bünning, C., additional, Ehehalt, R., additional, Howaldt, S., additional, Kucharzik, T., additional, Lamprecht, H.G., additional, Mudter, J., additional, Preiss, J.C., additional, Schreiber, S., additional, Seidler, U., additional, Altorjay, I., additional, Banai, J., additional, Lakatos, P.L., additional, Varga, M., additional, Vincze, A., additional, Avni-Biron, I., additional, Fishman, S., additional, Fraser, G.M., additional, Goldin, E., additional, Rachmilewitz, D., additional, Annese, V., additional, Ardizzone, S., additional, Biancone, L., additional, Bossa, F., additional, Danese, S., additional, Fries, W., additional, Gionchetti, P., additional, Maconi, G., additional, Terrosu, G., additional, Usai, P., additional, D'Haens, G.R., additional, Gearry, R.B., additional, Hill, J., additional, Rowbotham, D.S., additional, Schultz, M., additional, Stubbs, R.S., additional, Wallace, D., additional, Walmsley, R.S., additional, Wyeth, J., additional, Malecka-Panas, E., additional, Paradowski, L., additional, Regula, J., additional, Beales, I.P., additional, Campbell, S., additional, Hawthorne, A.B., additional, Parkes, M., additional, Travis, S.P., additional, Achkar, J.P., additional, Behm, B.W., additional, Bickston, S.J., additional, Brown, K.J., additional, Chiorean, M.V., additional, DeVilliers, W.J.S., additional, Elliott, D.E., additional, Grunkmeier, D., additional, Hamilton, J.W., additional, Hanauer, S.B., additional, Hanson, J.S., additional, Hardi, R., additional, Helper, D.J., additional, Herfarth, H., additional, Higgins, P.D.R., additional, Holderman, W.H., additional, Kottoor, R., additional, Kreines, M.D., additional, Leman, B.I., additional, Li, X., additional, Loftus, E.V., additional, Noar, M., additional, Oikonomou, I., additional, Onken, J., additional, Peterson, K.A., additional, Phillips, R.P., additional, Randall, C.W., additional, Ricci, M., additional, Ritter, T., additional, Rubin, D.T., additional, Safdi, M., additional, Sandborn, W.J., additional, Sauberman, L., additional, Scherl, E., additional, Schwarz, R.P., additional, Sedghi, S., additional, Shafran, I., additional, Sninsky, C.A., additional, Stein, I., additional, Swoger, J., additional, Vecchio, J., additional, Weinberg, D.I., additional, Wruble, L.D., additional, Yajnik, V., additional, and Younes, Z., additional

Published
2016
Full Text
View/download PDF

66. Vedolizumab as induction and maintenance therapy for ulcerative colitis

Author

Feagan, Bg, Rutgeerts, P, Sands, Be, Hanauer, S, Colombel, Jf, Sandborn, Wj, Van Assche, G, Axler, J, Kim, Hj, Danese, S, Fox, I, Milch, C, Sankoh, S, Wyant, T, Xu, J, Parikh, A, Bampton P, GEMINI 1 Study G. r. o. u. p., Chung, A, Debinski, H, Florin, T, Hetzel, D, Kronborg, I, Lawrance, I, Leong, R, Macrae, F, Moore, G, Pavli, P, Radford Smith, G, Weltman, M, Haas, T, Reinisch, W, Stockenhuber, F, Vogel, W, De Maeyer, M, De Vos, M, D'Haens, G, Louis, E, Muls, V, Petrov, P, Aumais, G, Bitton, A, Bourdages, R, Bressler, B, Cohen, A, Fedorak, R, Greenberg, G, Jones, J, Kutcher, W, Macintosh, D, Ponich, T, Singh, R, Steinhart, H, Sy, R, Douda, L, Lukas, M, Samek, M, Vyhnalek, P, Woznica, V, Zadorova, Z, Andersen, V, Rannem, T, Staun, M, Maelt, A, Margus, B, Bonaz, B, Coffin, B, Desreumaux, P, Laharie, D, Reimund, Jm, Karaus, M, Pace, A, Ross, M, Schmidt, W, Witthoeft, T, Zeitz, M, Karamanolis, D, Mantzaris, G, Maris, T, Ng, C, Gall, J, Hunyady, B, Szepes, A, Toth, T, Vincze, A, Oddsson, E, Jósefsspktali, Kö, Ahuja, V, Amarapurkar, D, Goenka, M, Habeeb, Ma, Jalihal, U, Kalambe, B, Koshy, A, Kumar, R, Prasad, V, Reddy, N, Sekar, T, Shankar, R, Tantry, V, Ryan, B, Avni, Y, Ben Horin, S, Ardizzone, S, Armuzzi, A, Corazziari, E, Fries, Walter, Kohn, A, Lisova, D, George, Am, Hilmi, In, Bhaskaran, Sk, Soon, Sy, Engels, L, Ponsioen, C, Wallace, I, Wyeth, J, Florholmen, J, Jahnsen, J, Lygren, I, Röseth, A, Ciecko Michalska, I, Gonciarz, M, Huk, J, Jamrozik Kruk, Z, Kondusz Szklarz, M, Paradowski, L, Wiechowska Kozlowska, A, Han, Ds, Hong, Sp, Kim, Js, Kim, Ko, Kim, Yh, Yang, Sk, Alexeeva, O, Bunkova, E, Burnevich, E, Dolgikh, O, Kasherininova, I, Khovaeva, Y, Lakhin, A, Ling, Kl, Bester, F, Coetzer, T, Grundling Hde, K, Jackson, Ld, Spies, P, Wright, Jp, Ziady, C, Garcia Planella, E, Perez Gisbert, J, Rogler, G, Seibold, F, Kao, Aw, Wu, Dc, Atug, O, Kurdas, Oo, Hawthorne, Ab, Lindsay, J, Abreu, M, Aggarwal, A, Bala, N, Becker, S, Behm, B, Braun, R, Cohn, W, Cross, R, Dar, S, Dassopoulos, T, De Villiers, W, Desta, T, Dryden, G, Duvall, A, Farraye, F, Fein, S, Liu, Bf, Gatof, D, Geenen, D, Ginsburg, P, Glover, S, Gopal, V, Hanson, J, Hardi, R, Isaacs, K, Jain, R, Karyotakis, N, Korzenik, J, Koshy, G, Koval, G, Lawitz, E, Lee, S, Loftus, E, Luther, R, Mahadevan, U, Mannon, P, Matsuyama, R, Mcintosh, A, Melmed, G, Mirkin, K, Nichols, M, Oubre, B, Pandak, W, Quadri, A, Quallich, L, Randall, C, Rausher, D, Regueiro, M, Safdi, A, Sands, B, Scherl, E, Schneier, J, Schwartz, D, Sedghi, S, Shafran, I, Siegel, C, Stein, L, Tatum, H, Weinberg, D, Winston, B, Wolf, D, Younes, Z, Jewell, D, Mahon, J, Rothstein, R, Snydman, D, Massaro, J, Clifford, D, Berger, J, Major, E, Provenzale, J, Abstract, Lev M., Feagan, Bg, Rutgeerts, P, Sands, Be, Hanauer, S, Colombel, Jf, Sandborn, Wj, Van Assche, G, Axler, J, Kim, Hj, Danese, S, Fox, I, Milch, C, Sankoh, S, Wyant, T, Xu, J, and Parikh, A

Subjects
Adult, Male, medicine.medical_specialty, Integrins, Placebo, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, law.invention, Vedolizumab, Maintenance Chemotherapy, Maintenance therapy, Randomized controlled trial, Double-Blind Method, law, Internal medicine, medicine, Humans, Glucocorticoids, Aged, business.industry, General Medicine, Induction Chemotherapy, Middle Aged, medicine.disease, Ulcerative colitis, Infliximab, Surgery, Clinical trial, Cohort, Colitis, Ulcerative, Drug Therapy, Combination, Female, business, Immunosuppressive Agents, medicine.drug
Abstract

Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis.We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with disease evaluation at week 6. In the trial of maintenance therapy, patients in either cohort who had a response to vedolizumab at week 6 were randomly assigned to continue receiving vedolizumab every 8 or 4 weeks or to switch to placebo for up to 52 weeks. A response was defined as a reduction in the Mayo Clinic score (range, 0 to 12, with higher scores indicating more active disease) of at least 3 points and a decrease of at least 30% from baseline, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.Response rates at week 6 were 47.1% and 25.5% among patients in the vedolizumab group and placebo group, respectively (difference with adjustment for stratification factors, 21.7 percentage points; 95% confidence interval [CI], 11.6 to 31.7; P0.001). At week 52, 41.8% of patients who continued to receive vedolizumab every 8 weeks and 44.8% of patients who continued to receive vedolizumab every 4 weeks were in clinical remission (Mayo Clinic score ≤2 and no subscore1), as compared with 15.9% of patients who switched to placebo (adjusted difference, 26.1 percentage points for vedolizumab every 8 weeks vs. placebo [95% CI, 14.9 to 37.2; P0.001] and 29.1 percentage points for vedolizumab every 4 weeks vs. placebo [95% CI, 17.9 to 40.4; P0.001]). The frequency of adverse events was similar in the vedolizumab and placebo groups.Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.).

Published
2013

67. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis

Author

Beaudoin, Melissa, Goyette, Philippe, Goel, Gautam, Louis, E., Mansfield, J. C., Mathew, C. G., McGovern, D. P., Mitrovic, M., Montgomery, G. W., Mowat, C., Newman, W., Palmieri, O., Panés, J., Lagace, Caroline, Parkes, M., Phillips, A., Ponsioen, C. Y., Potocnik, U., Prescott, N. J., Proctor, D. D., Radford-Smith, G. L., Regueiro, M., Rioux, J. D., Roberts, R., Annese, Vito, Rotter, J. I., Rutgeerts, P., Sanderson, J., Sans, M., Satsangi, J., Schreiber, S., Schumm, P., Seibold, F., Sharma, Y., Silverberg, M. S., Bitton, Alain, Simms, L. A., Steinhart, A., Targan, S. R., Taylor, K. D., Torkvist, L., Vermeire, S., Halfvarson, J., Verspaget, H. W., De Vos, M., Walters, T., Begun, Jakob, Wang, K., Weersma, R. K., Whiteman, D., Wijmenga, C., Brant, Steven R., Bresso, Francesca, Cho, Judy H., Duerr, Richard H., Halfvarson, Jonas, Boucher, Gabrielle, McGovern, Dermot P. B., Radford-Smith, Graham, Schreiber, Stefan, Schumm, Philip L., Sharma, Yashoda, Silverberg, Mark S., Weersma, Rinse K., Quebec IBD Genetics Consortium, NIDDK IBD Genetics Consortium, International IBD Genetics Consortium (IIBDGC), Lo, Ken Sin, D'Amato, Mauro, Vermeire, Severine, Franke, Andre, Lettre, Guillaume, Xavier, Ramnik J., Daly, Mark J., Rioux, John D., Aumais, G., Bernard, E. J., Bitton, A., Rivas, Manuel A., Cohen, A., Deslandres, C., Lahaie, R., Paré, P., Brant, S. R., Cho, J. H., Duerr, R. H., Stevens, Christine, Ahmad, T., Anderson, C. A., Annese, V., Baldassano, R. N., Balschun, T., Barclay, M., Barrett, J. C., Bayless, T. M., Bis, J. C., Alikashani, Azadeh, Brand, S., Bumpstead, S., Buning, C., Colombel, J. F., Cottone, M., D'Amato, M., D'Inca, R., Ladouceur, Martin, Daly, M. J., Denson, T., Dubinsky, M., Edwards, C., Ellinghaus, D., Florin, T., Franchimont, D., Franke, A., Gearry, R., Ellinghaus, David, Georges, M., Glas, J., Van Gossum, A., Griffiths, A. M., Guthery, S. L., Hakonarson, H., Haritunians, T., Hugot, J. P., de Jong, D. J., Jostins, L., Torkvist, Leif, Kugathasan, S., Kullak-Ublick, G., Latiano, A., Laukens, D., Lawrance, I., Lee, J., Lees, C. W., Lemann, M., Levine, A., Libioulle, C., and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)

Subjects
Cancer Research, Génétique clinique, LIVER, Genome-wide association study, Inflammatory bowel disease, 0302 clinical medicine, Crohn Disease, GENETIC-VARIANTS, Medicine and Health Sciences, Ethnicity, UBIQUITIN LIGASES, Genetics(clinical), Genetics (clinical), Genetics, 0303 health sciences, Ecology, High-Throughput Nucleotide Sequencing, CROHN-DISEASE, CROHNS-DISEASE, 3. Good health, 030220 oncology & carcinogenesis, Medical genetics, Biologie, Research Article, EXPRESSION, medicine.medical_specialty, Canada, lcsh:QH426-470, SUSCEPTIBILITY LOCI, Evolution, Ubiquitin-Protein Ligases, Ethnic Groups, Evolution des espèces, Biology, Molecular gastro-enterology and hepatology Pathogenesis and modulation of inflammation [IGMD 2], Polymorphism, Single Nucleotide, 03 medical and health sciences, Behavior and Systematics, medicine, Humans, Genetic Predisposition to Disease, Ligase activity, MODULATION, Allele, GENOME-WIDE ASSOCIATION, Molecular Biology, Genotyping, Ecology, Evolution, Behavior and Systematics, 030304 developmental biology, Genetic association, Ecologie, Biologie moléculaire, Receptors, Interleukin, medicine.disease, NUCLEAR FACTOR 4-ALPHA, Genetic architecture, Cancérologie, CARD Signaling Adaptor Proteins, lcsh:Genetics, CELLS, Colitis, Ulcerative, INTESTINAL EPITHELIAL-CELLS, Genome-Wide Association Study, INFLAMMATORY-BOWEL-DISEASE
Abstract

Genome-wide association studies and follow-up meta-analyses in Crohn's disease (CD) and ulcerative colitis (UC) have recently identified 163 disease-associated loci that meet genome-wide significance for these two inflammatory bowel diseases (IBD). These discoveries have already had a tremendous impact on our understanding of the genetic architecture of these diseases and have directed functional studies that have revealed some of the biological functions that are important to IBD (e.g. autophagy). Nonetheless, these loci can only explain a small proportion of disease variance (~14% in CD and 7.5% in UC), suggesting that not only are additional loci to be found but that the known loci may contain high effect rare risk variants that have gone undetected by GWAS. To test this, we have used a targeted sequencing approach in 200 UC cases and 150 healthy controls (HC), all of French Canadian descent, to study 55 genes in regions associated with UC. We performed follow-up genotyping of 42 rare non-synonymous variants in independent case-control cohorts (totaling 14,435 UC cases and 20,204 HC). Our results confirmed significant association to rare non-synonymous coding variants in both IL23R and CARD9, previously identified from sequencing of CD loci, as well as identified a novel association in RNF186. With the exception of CARD9 (OR = 0.39), the rare non-synonymous variants identified were of moderate effect (OR = 1.49 for RNF186 and OR = 0.79 for IL23R). RNF186 encodes a protein with a RING domain having predicted E3 ubiquitin-protein ligase activity and two transmembrane domains. Importantly, the disease-coding variant is located in the ubiquitin ligase domain. Finally, our results suggest that rare variants in genes identified by genome-wide association in UC are unlikely to contribute significantly to the overall variance for the disease. Rather, these are expected to help focus functional studies of the corresponding disease loci. © 2013 Beaudoin et al., 0, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2013

68. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Author

Anderson, C.A. Boucher, G. Lees, C.W. Franke, A. D'Amato, M. Taylor, K.D. Lee, J.C. Goyette, P. Imielinski, M. Latiano, A. Lagacé, C. Scott, R. Amininejad, L. Bumpstead, S. Baidoo, L. Baldassano, R.N. Barclay, M. Bayless, T.M. Brand, S. Büning, C. Colombel, J.-F. Denson, L.A. De Vos, M. Dubinsky, M. Edwards, C. Ellinghaus, D. Fehrmann, R.S.N. Floyd, J.A.B. Florin, T. Franchimont, D. Franke, L. Georges, M. Glas, J. Glazer, N.L. Guthery, S.L. Haritunians, T. Hayward, N.K. Hugot, J.-P. Jobin, G. Laukens, D. Lawrance, I. Lémann, M. Levine, A. Libioulle, C. Louis, E. McGovern, D.P. Milla, M. Montgomery, G.W. Morley, K.I. Mowat, C. Ng, A. Newman, W. Ophoff, R.A. Papi, L. Palmieri, O. Peyrin-Biroulet, L. Panés, J. Phillips, A. Prescott, N.J. Proctor, D.D. Roberts, R. Russell, R. Rutgeerts, P. Sanderson, J. Sans, M. Schumm, P. Seibold, F. Sharma, Y. Simms, L.A. Seielstad, M. Steinhart, A.H. Targan, S.R. Van Den Berg, L.H. Vatn, M. Verspaget, H. Walters, T. Wijmenga, C. Wilson, D.C. Westra, H.-J. Xavier, R.J. Zhao, Z.Z. Ponsioen, C.Y. Andersen, V. Torkvist, L. Gazouli, M. Anagnou, N.P. Karlsen, T.H. Kupcinskas, L. Sventoraityte, J. Mansfield, J.C. Kugathasan, S. Silverberg, M.S. Halfvarson, J. Rotter, J.I. Mathew, C.G. Griffiths, A.M. Gearry, R. Ahmad, T. Brant, S.R. Chamaillard, M. Satsangi, J. Cho, J.H. Schreiber, S. Daly, M.J. Barrett, J.C. Parkes, M. Annese, V. Hakonarson, H. Radford-Smith, G. Duerr, R.H. Vermeire, S. Weersma, R.K. Rioux, J.D.

Abstract

Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association study datasets, comprising 6,687 cases and 19,718 controls, and followed up the top association signals in 9,628 cases and 12,917 controls. We identified 29 additional risk loci (P < 5 × 10-8), increasing the number of ulcerative colitis-associated loci to 47. After annotating associated regions using GRAIL, expression quantitative trait loci data and correlations with non-synonymous SNPs, we identified many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1. The total number of confirmed inflammatory bowel disease risk loci is now 99, including a minimum of 28 shared association signals between Crohn's disease and ulcerative colitis. © 2011 Nature America, Inc. All rights reserved.

Published
2011

69. Effect of Intestinal Resection on Quality of Life in Crohn's Disease

Author

Wright, E. K., primary, Kamm, M. A., additional, De Cruz, P., additional, Hamilton, A. L., additional, Ritchie, K. J., additional, Krejany, E. O., additional, Gorelik, A., additional, Liew, D., additional, Prideaux, L., additional, Lawrance, I. C., additional, Andrews, J. M., additional, Bampton, P. A., additional, Sparrow, M. P., additional, Florin, T. H., additional, Gibson, P. R., additional, Debinski, H., additional, Gearry, R. B., additional, Macrae, F. A., additional, Leong, R. W., additional, Kronborg, I., additional, Radford-Smith, G., additional, Selby, W., additional, Johnston, M. J., additional, Woods, R., additional, Elliott, P. R., additional, Bell, S. J., additional, Brown, S. J., additional, Connell, W. R., additional, and Desmond, P. V., additional

Published
2015
Full Text
View/download PDF

73. P609 5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease

Author

So, K., primary, Bewshea, C., additional, Heap, G., additional, Muller, A., additional, Delaney, M., additional, Daneshmend, T., additional, Mulgrew, C., additional, D'Souza, R., additional, Kwan, J., additional, Irving, P., additional, Orchard, T., additional, Hart, A., additional, Tsianos, E., additional, Annese, V., additional, Silverberg, M., additional, Watermeyer, G., additional, Renata, D., additional, Radford-Smith, G., additional, Gearry, R., additional, Oram, R., additional, Russell, R., additional, Wilson, D., additional, Parkes, M., additional, Satsangi, J., additional, Weersma, R., additional, Lawrance, I., additional, Holden, A., additional, Lees, C., additional, and Ahmad, T., additional

Published
2013
Full Text
View/download PDF

74. P365 Smoking and the effect of its cessation on Crohn's disease progression and surgical rates

Author

Lawrance, I., primary, Murray, K., additional, Batman, B., additional, Gearry, R., additional, Grafton, R., additional, Krishnaprasad, K., additional, Andrews, J., additional, Prosser, R., additional, Bampton, P., additional, Cooke, S., additional, Mahy, G., additional, Radford-Smith, G., additional, Croft, A., additional, and Hanigan, K., additional

Published
2013
Full Text
View/download PDF

75. Review article: acute severe ulcerative colitis - evidence-based consensus statements.

Author

Chen, J.‐H., Andrews, J. M., Kariyawasam, V., Moran, N., Gounder, P., Collins, G., Walsh, A. J., Connor, S., Lee, T. W. T., Koh, C. E., Chang, J., Paramsothy, S., Tattersall, S., Lemberg, D. A., Radford‐Smith, G., Lawrance, I. C., McLachlan, A., Moore, G. T., Corte, C., and Katelaris, P.

Subjects
ULCERATIVE colitis, CYTOMEGALOVIRUS diseases, THROMBOEMBOLISM, HYDROCORTISONE, DELPHI method
Abstract

Background Acute severe ulcerative colitis ( ASUC) is a potentially life-threatening complication of ulcerative colitis. Aim To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome. Methods Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre-determined by ≥80% votes in 'complete agreement' or 'agreement with minor reservation'. Results Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres. Conclusion These evidenced-based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up-to-date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

77. P342 Adalimumab prevents post-operative Crohn's disease recurrence and is superior to thiopurines: Early results from the prospective POCER study

Author

De Cruz, P., primary, Kamm, M., additional, Hamilton, A.L., additional, Ritchie, K., additional, Gorelik, A., additional, Liew, D., additional, Prideaux, L., additional, Lawrance, I., additional, Andrews, J.M., additional, Bampton, P., additional, Sparrow, M., additional, Jakobovits, S., additional, Florin, T., additional, Gibson, P., additional, Debinski, H., additional, Gearry, R., additional, Macrae, F., additional, Leong, R., additional, Kronborg, I., additional, Connor, S., additional, Pavli, P., additional, Smith, G. Radford, additional, Selby, W., additional, Johnston, M., additional, Brouwer, R., additional, Keck, J.O., additional, Woods, R., additional, Connell, W., additional, Brown, S.J., additional, Bell, S.J., additional, Lust, M., additional, Elliott, R., additional, and Desmond, P.V., additional

Published
2012
Full Text
View/download PDF

78. P372 Predicting long-term response to anti-TNFα in Crohn's disease

Author

Hartnell, F., primary, Jones, L., additional, Bampton, P., additional, Krishnaprasad, K., additional, Grafton, R., additional, Cooke, S., additional, Mahy, G., additional, Prosser, R., additional, Moss, K., additional, Ding, J., additional, Tehan, J., additional, De Cruz, P., additional, Marr, D., additional, Lawrance, I., additional, Fischer, J., additional, Thomas, G., additional, Gearry, R., additional, Grover, Z., additional, Lewindon, P., additional, Croft, A., additional, Sewell, K., additional, O'Rourke, P., additional, Andrews, J.M., additional, and Radford-Smith, G., additional

Published
2012
Full Text
View/download PDF

91. Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohnʼs Disease Who Failed Prior Anti-TNFα Therapy

Author

Lashner, B., primary, Colombel, J. F., additional, Enns, R., additional, Feagan, B. G., additional, Fedorak, R. N., additional, Hanauer, S. B., additional, Lawrance, I. C., additional, Panaccione, R., additional, Present, D., additional, Rutgeerts, P., additional, Sandborn, W. J., additional, Sanders, M., additional, Schreiber, S., additional, Spehlmann, M. E., additional, Tulassay, Z., additional, van Deventer, S., additional, Volfova, M., additional, Wolf, D. C., additional, and Targan, S., additional

Published
2007
Full Text
View/download PDF

92. Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteriods for the Induction of Sustained Response and Remission in Patients with Crohnʼs Disease

Author

Wolf, D. C., primary, Colombel, J. F., additional, Enns, R., additional, Feagan, B. G., additional, Fedorak, R. N., additional, Hanauer, S. B., additional, Lashner, B., additional, Lawrance, I. C., additional, Panaccione, R., additional, Present, D., additional, Rutgeerts, P., additional, Sandborn, W. J., additional, Sanders, M., additional, Schreiber, S., additional, Spehlmann, M. E., additional, Tulassay, Z., additional, van Deventer, S., additional, Volfova, M., additional, and Targan, S., additional

Published
2007
Full Text
View/download PDF

94. Natalizumab Maintains Remission for 2 Years in Patients with Moderately to Severely Active Crohnʼs Disease and in Those with Prior Infliximab Exposure

Author

Panaccione, R., primary, Colombel, J. F., additional, Enns, R., additional, Feagan, B., additional, Hanauer, S., additional, Lawrance, I., additional, Rutgeerts, P., additional, Sandborn, W. J., additional, Sanders, M., additional, Schreiber, S., additional, Targan, S., additional, and VanDeventer, S., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results